文献速递药物不良反应与药物警戒

日本患者与JADER数据库药品不良反应报告特征及趋势对比分析

Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database.
PubMed 文献 · Br J Clin Pharmacol · 2025-09-20

结果显示患者报告者多为30-50岁女性,主诉疲劳、头痛等生活质量相关症状,常涉及中枢神经系统药物;专业报告则多为60-80岁男性,聚焦间质性肺病、肺炎等严重状况,常与抗癌药相关。两种报告体系互补,患者报告为上市后药物安全监测提供了有价值的信息。

要点

  • 患者报告以年轻女性为主,侧重疲劳、头痛等主观生活质量症状,常涉及中枢神经系统药物。
  • JADER专业报告以老年男性为主,聚焦间质性肺病、肺炎等严重状况,常与抗癌药相关。
  • 患者与专业报告在人口学特征和关注点上存在差异,两者互补可提升上市后药物警戒。

核心结论

  • 患者药品不良反应报告为药物安全监测提供了有价值的补充信息。
  • 患者与专业报告虽存在差异,但共同改善了药品上市后监测。

研究设计与样本

  • 利用日本医药品医疗器械综合机构网站2019年3月至2024年3月的患者报告,以及2019年1月至2024年3月的JADER报告。
  • 分析人口学信息、涉及药物、不良反应类型及结局,并比较两组报告的频率与特征。

主要发现

  • 患者报告者年龄多在30-50岁,以女性为主;JADER报告者年龄多在60-80岁,以男性为主。
  • 患者报告常见疲劳、头痛等主观症状,常与中枢神经系统靶向药物相关。
  • JADER报告聚焦间质性肺病、肺炎等严重状况,常与抗癌药物相关。
  • 患者报告突出与生活质量相关的症状,专业报告则更多报告严重医学状况。

临床怎么用

  • 临床药学智能体应识别患者报告与专业报告在症状类型和药物类别上的差异,综合评估药物安全信号。
  • 在药物警戒中可鼓励患者通过电话等多种途径提交报告,以增强监测系统的包容性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends. METHODS: ADR reports from the Pharmaceuticals and Medical Devices Agency website, including patient reports from March 2019 to March 2024, and JADER reports from January 2019 to March 2024, were utilized. Information on demographics, drugs, ADR types and outcomes was analysed. Frequencies and comparisons between the two reporting groups were performed. RESULTS: A total of 2913 patient reports and 343 894 JADER reports were analysed. Patients were often younger (30-50 years) and mostly female, whereas JADER reports included older patients (60-80 years) and mostly male. Patients reported subjective symptoms, such as fatigue and headache, often associated with drugs targeting the central nervous system. In contrast, JADER reports focused on serious conditions, such as interstitial lung disease and pneumonia, which are commonly associated with anticancer drugs. Patient and professional ADR reports differed in focus. Patients highlighted quality-of-life-related symptoms, whereas professionals reported more serious medical conditions. Differences in demographics and reporting methods indicate that these systems are complementary. Offering more reporting options, such as telephone-based submissions, can make the system more inclusive. CONCLUSIONS: The study highlights how patient ADR reports provide valuable insights into drug safety. Although differences exist, patient and professional reports improve monitoring after drug approval.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Tsuchiya M, Funakoshi R, Masuyama K, et al. Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database. Br J Clin Pharmacol. 2025. PMID: 40974228. doi:10.1002/bcp.70291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。